{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:08:18Z","timestamp":1794650898110,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prostate cancer (PCa) is a prevalent malignant tumor of the urinary system and remains the most common cancer among males. In this study, we showed that YTHDF1, one of the reader proteins involved in the N6-methyladenosine (m6A) modification signaling pathway, is highly expressed in PCa cancerous tissues and cells, which correlates with poor clinical outcomes. Our study revealed that YTHDF1 knockdown inhibits tumor cell proliferation, migration, and xenograft tumor formation by decreasing p27 protein stability through proteasome degradation signaling. Consistently, YTHDF1 depletion markedly reduced the clonogenic growth of <jats:italic>Pten<\/jats:italic> or\/and <jats:italic>TP53<\/jats:italic>-deficient organoids. Candidate p27-targeting E3 ubiquitin ligases screening identified RNF7 as the direct downstream target for YTHDF1 in an m6A-dependent manner. The subsequent high translation of RNF7 results in the efficient degradation of the cell cycle inhibitor p27 and malignant tumor cell growth. In addition, we provided evidence showing that YTHDF1 or RNF7 depletion sensitizes tumor cells to chemotherapy drug cisplatin by increasing cellular apoptosis. Our findings revealed that the neddylation inhibitor MLN4924 effectively inhibited prostate cancer progression in vitro and in vivo. Our study highlights the YTHDF1\/RNF7\/p27 axis as a crucial component in PCa, suggesting its potential as a novel therapeutic target.<\/jats:p>","DOI":"10.1038\/s41419-025-07648-3","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T17:39:56Z","timestamp":1744997996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["YTHDF1\/RNF7\/p27 axis promotes prostate cancer progression"],"prefix":"10.1038","volume":"16","author":[{"given":"Yulin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqing","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengcai","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6534-6991","authenticated-orcid":false,"given":"Yongbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"7648_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7648_CR2","doi-asserted-by":"crossref","unstructured":"Pej\u010di\u0107 T, Todorovi\u0107 Z, \u0110ura\u0161evi\u0107 S, Popovi\u0107 L. Mechanisms of prostate cancer cells survival and their therapeutic targeting. Int J Mol Sci. 2023;24:2939.","DOI":"10.3390\/ijms24032939"},{"key":"7648_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016;66:115\u201332.","journal-title":"Cancer J Clin"},{"key":"7648_CR4","first-page":"S148","volume":"197","author":"MC Wang","year":"2017","unstructured":"Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. J Urol. 2017;197:S148\u2013s152.","journal-title":"J Urol"},{"key":"7648_CR5","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","volume":"267","author":"HB Carter","year":"1992","unstructured":"Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Jama. 1992;267:2215\u201320.","journal-title":"Jama"},{"key":"7648_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/jnci\/djp001","volume":"101","author":"G Draisma","year":"2009","unstructured":"Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"7648_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.eururo.2010.02.003","volume":"57","author":"FH Jansen","year":"2010","unstructured":"Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010;57:921\u20137.","journal-title":"Eur Urol"},{"key":"7648_CR8","doi-asserted-by":"crossref","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.","DOI":"10.3390\/molecules27175730"},{"key":"7648_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4103\/aja.aja_19_19","volume":"21","author":"G Gritsina","year":"2019","unstructured":"Gritsina G, Gao WQ, Yu J. Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer. Asian J Androl. 2019;21:215\u201323.","journal-title":"Asian J Androl"},{"key":"7648_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"7648_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12801-6","volume":"10","author":"Y Shi","year":"2019","unstructured":"Shi Y, Fan S, Wu M, Zuo Z, Li X, Jiang L, et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019;10:4892.","journal-title":"Nat Commun"},{"key":"7648_CR12","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.7150\/thno.19425","volume":"7","author":"QG Li","year":"2017","unstructured":"Li QG, He YH, Wu H, Yang CP, Pu SY, Fan SQ, et al. A normalization-free and nonparametric method sharpens large-scale transcriptome analysis and reveals common gene alteration patterns in cancers. Theranostics. 2017;7:2888\u201399.","journal-title":"Theranostics"},{"key":"7648_CR13","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 1974;71:3971\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7648_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.","journal-title":"Signal Transduct Target Ther"},{"key":"7648_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.molcel.2016.04.024","volume":"62","author":"U Schumann","year":"2016","unstructured":"Schumann U, Shafik A, Preiss T. METTL3 gains R\/W access to the epitranscriptome. Mol Cell. 2016;62:323\u20134.","journal-title":"Mol Cell"},{"key":"7648_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93\u201395.","journal-title":"Nat Chem Biol"},{"key":"7648_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/cr.2014.3","volume":"24","author":"XL Ping","year":"2014","unstructured":"Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177\u201389.","journal-title":"Cell Res"},{"key":"7648_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-cellbio-100616-060758","volume":"33","author":"KD Meyer","year":"2017","unstructured":"Meyer KD, Jaffrey SR. Rethinking m(6)a readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33:319\u201342.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"7648_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.celrep.2014.05.048","volume":"8","author":"S Schwartz","year":"2014","unstructured":"Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, Bushkin GG, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5\u2019 sites. Cell Rep. 2014;8:284\u201396.","journal-title":"Cell Rep"},{"key":"7648_CR20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885\u20137.","journal-title":"Nat Chem Biol"},{"key":"7648_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1459057","volume":"15","author":"G Song","year":"2024","unstructured":"Song G, Liu J, Tang X, Zhong J, Zeng Y, Zhang X, et al. Cell cycle checkpoint revolution: targeted therapies in the fight against malignant tumors. Front Pharm. 2024;15:1459057.","journal-title":"Front Pharm"},{"key":"7648_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1172\/JCI123557","volume":"129","author":"Y Ding","year":"2019","unstructured":"Ding Y, Li N, Dong B, Guo W, Wei H, Chen Q, et al. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest. 2019;129:759\u201373.","journal-title":"J Clin Invest"},{"key":"7648_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.cell.2007.05.022","volume":"129","author":"JL Rinn","year":"2007","unstructured":"Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129:1311\u201323.","journal-title":"Cell"},{"key":"7648_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.chembiol.2021.04.008","volume":"28","author":"S Duan","year":"2021","unstructured":"Duan S, Pagano M. Ubiquitin ligases in cancer: functions and clinical potentials. Cell Chem Biol. 2021;28:918\u201333.","journal-title":"Cell Chem Biol"},{"key":"7648_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/1947601910382776","volume":"1","author":"D Wei","year":"2010","unstructured":"Wei D, Sun Y. Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets. Genes Cancer. 2010;1:700\u20137.","journal-title":"Genes Cancer"},{"key":"7648_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/jcmm.17656","volume":"27","author":"N Tang","year":"2023","unstructured":"Tang N, Zhu K, Jiang C, Xiong Z, Wang Q, Li J, et al. RNF7 promotes glioma growth via the PI3K\/AKT signalling axis. J Cell Mol Med. 2023;27:277\u201386.","journal-title":"J Cell Mol Med"},{"key":"7648_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s11658-022-00337-5","volume":"27","author":"C Xiao","year":"2022","unstructured":"Xiao C, Zhang W, Hua M, Chen H, Yang B, Wang Y, et al. RNF7 inhibits apoptosis and sunitinib sensitivity and promotes glycolysis in renal cell carcinoma via the SOCS1\/JAK\/STAT3 feedback loop. Cell Mol Biol Lett. 2022;27:36.","journal-title":"Cell Mol Biol Lett"},{"key":"7648_CR28","doi-asserted-by":"publisher","DOI":"10.1063\/5.0126095","volume":"6","author":"S Peng","year":"2022","unstructured":"Peng S, Zhang X, Huang H, Cheng B, Xiong Z, Du T, et al. Glutathione-sensitive nanoparticles enhance the combined therapeutic effect of checkpoint kinase 1 inhibitor and cisplatin in prostate cancer. APL Bioeng. 2022;6:046106.","journal-title":"APL Bioeng"},{"key":"7648_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0891-5849(99)00078-7","volume":"27","author":"M Swaroop","year":"1999","unstructured":"Swaroop M, Bian J, Aviram M, Duan H, Bisgaier CL, Loo JA, et al. Expression, purification, and biochemical characterization of SAG, a ring finger redox-sensitive protein. Free Radic Biol Med. 1999;27:193\u2013202.","journal-title":"Free Radic Biol Med"},{"key":"7648_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732\u20136.","journal-title":"Nature"},{"key":"7648_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-020-00453-8","volume":"6","author":"Q Li","year":"2021","unstructured":"Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H, et al. HIF-1\u03b1-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther. 2021;6:76.","journal-title":"Signal Transduct Target Ther"},{"key":"7648_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1088-x","volume":"18","author":"R Jia","year":"2019","unstructured":"Jia R, Chai P, Wang S, Sun B, Xu Y, Yang Y, et al. m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 2019;18:161.","journal-title":"Mol Cancer"},{"key":"7648_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/j.gastro.2021.12.269","volume":"162","author":"S Wang","year":"2022","unstructured":"Wang S, Gao S, Zeng Y, Zhu L, Mo Y, Wong CC, et al. N6-methyladenosine reader YTHDF1 promotes ARHGEF2 translation and RhoA signaling in colorectal cancer. Gastroenterology. 2022;162:1183\u201396.","journal-title":"Gastroenterology"},{"key":"7648_CR34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fonc.2019.00332","volume":"9","author":"Y Bai","year":"2019","unstructured":"Bai Y, Yang C, Wu R, Huang L, Song S, Li W, et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 2019;9:332.","journal-title":"Front Oncol"},{"key":"7648_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41420-023-01321-4","volume":"9","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Li J, Yang H, Yang X, Zhang Y, Yu X, et al. The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer. Cell Death Discov. 2023;9:34.","journal-title":"Cell Death Discov"},{"key":"7648_CR36","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1158\/1078-0432.CCR-09-1592","volume":"16","author":"L Jia","year":"2010","unstructured":"Jia L, Yang J, Hao X, Zheng M, He H, Xiong X, et al. Validation of SAG\/RBX2\/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res J Am Assoc Cancer Res. 2010;16:814\u201324.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"7648_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s13238-012-2105-7","volume":"4","author":"Y Sun","year":"2013","unstructured":"Sun Y, Li H. Functional characterization of SAG\/RBX2\/ROC2\/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein cell. 2013;4:103\u201316.","journal-title":"Protein cell"},{"key":"7648_CR38","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-12-0388","volume":"72","author":"Z Luo","year":"2012","unstructured":"Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 2012;72:3360\u201371.","journal-title":"Cancer Res"},{"key":"7648_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep24218","volume":"6","author":"H Lan","year":"2016","unstructured":"Lan H, Tang Z, Jin H, Sun Y. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci Rep. 2016;6:24218.","journal-title":"Sci Rep"},{"key":"7648_CR40","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/cdd.2015.74","volume":"22","author":"KL Knorr","year":"2015","unstructured":"Knorr KL, Schneider PA, Meng XW, Dai H, Smith BD, Hess AD, et al. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death Differ. 2015;22:2133\u201342.","journal-title":"Cell Death Differ"},{"key":"7648_CR41","doi-asserted-by":"crossref","unstructured":"Meng L, Yang Y, Mortazavi A, Zhang J. Emerging immunotherapy approaches for treating prostate cancer. Int J Mol Sci. 2023;24:14347.","DOI":"10.3390\/ijms241814347"},{"key":"7648_CR42","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","volume":"23","author":"M Bilusic","year":"2017","unstructured":"Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin Cancer Res. 2017;23:6764\u201370.","journal-title":"Clin Cancer Res"},{"key":"7648_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670490","volume":"11","author":"G Yan","year":"2021","unstructured":"Yan G, An Y, Xu B, Wang N, Sun X, Sun M. Potential impact of ALKBH5 and YTHDF1 on tumor immunity in colon adenocarcinoma. Front Oncol. 2021;11:670490.","journal-title":"Front Oncol"},{"key":"7648_CR44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","volume":"566","author":"D Han","year":"2019","unstructured":"Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019;566:270\u20134.","journal-title":"Nature"},{"key":"7648_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.607224","volume":"11","author":"J Hu","year":"2021","unstructured":"Hu J, Qiu D, Yu A, Hu J, Deng H, Li H, et al. YTHDF1 is a potential pan-cancer biomarker for prognosis and immunotherapy. Front Oncol. 2021;11:607224.","journal-title":"Front Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07648-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T19:02:10Z","timestamp":1745002930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07648-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7648"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07648-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Samples were obtained with informed consent, and all protocols were approved by Department of Pathology, Cancer Hospital of China Medical University (Scientific and Research Ethics Committee, 20201001). Written informed consent was obtained from all patients, also the written informed consent was obtained from the next of kin, caretakers, or guardians on behalf of the minors\/children participants involved in this study. Mouse care and treatment were approved by the Animal Care and Use Committee at the Kunming Institute of Zoology, Chinese Academy of Sciences (Scientific and Research Ethics Committee, IACUC-RE-2024-08-009).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"314"}}